Colon Cancer, Prostate Cancer
Conditions
Keywords
Solid tumor, prostate cancer, colon cancer
Brief summary
The objective of this study is to obtain blood samples, solid tumor and/or benign hyperplasia samples to learn more about genetic differences that are linked to the formation of solid tumors.
Detailed description
Recent studies in human genetics have discovered several intervals in the human genome containing inherited variants that are statistically associated with the propensity to develop solid tumors. Even though it has been firmly established that if an individual carries these DNA variants they have an increased chance of developing a solid tumor the underlying biological mechanisms for most of these associations are largely unknown. In addition to inherited DNA variants that are associated with the development of solid tumors it is well established that during the development and growth of solid tumors the DNA in these cancer cells undergo somatic changes (mutations). These somatic DNA changes have been studied over the past decade and frequently are specific chromosomal translocations and amplifications associated with the development of particular solid tumors. In some instances, examining the chromosomal translocation and amplification has lead to the discovery of proteins contributing to solid tumor pathology. the human 8q24 interval that has strong genetic associations with solid tumor development has also been noted as frequently amplified in solid tumors and serves as a predictor of poor survival in prostate cancers.
Interventions
None listed
Sponsors
Scripps Translational Science Institute
Study design
Observational model
COHORT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age 18 years or older 2. Eligible to have their blood drawn 3. Be reliable, cooperative and willing to comply with all protocol-specified procedures 4. Able to understand and grant informed consent 5. Diagnosis of a solid tumor
Exclusion criteria
1. Has a significant chronic medical condition which would potentially confound interpretation of the individual's phenotype. 2. Treatment with any investigational agents or devices within thirty days preceding enrollment in the study. 3. Been administered or taken any CNS sedatives or depressants in the 12 hours prior to informed consent process
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Solid tumor biological insights | Study completion | Obtain blood samples, solid tumor and/or benign hyperplasia samples, and in some instances normal tissue in order to gain biological insights into cancer (solid tumors) through population genetics and genomics. |
Countries
United States
Outcome results
None listed